BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28918185)

  • 21. Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: a systematic review.
    Bhangu A; Broom L; Nepogodiev D; Gourevitch D; Desai A
    Eur J Surg Oncol; 2013 Apr; 39(4):311-9. PubMed ID: 23351681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept].
    Schwarzbach M; Lehnert T; Willeke F; Hinz U; Herfarth C
    Chirurg; 1996 Dec; 67(12):1237-43. PubMed ID: 9081786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
    Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
    Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity.
    Olofsson R; Bergh P; Berlin O; Engström K; Gunterberg B; Hansson M; Lindnér P; Mattsson J
    Ann Surg Oncol; 2012 Jun; 19(6):1800-7. PubMed ID: 22219068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
    Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis.
    van Broekhoven DL; Deroose JP; Bonvalot S; Gronchi A; Grünhagen DJ; Eggermont AM; Verhoef C
    Br J Surg; 2014 Dec; 101(13):1674-80. PubMed ID: 25296896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
    Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
    J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histological response assessment following neoadjuvant isolated limb perfusion in patients with primary, localised, high-grade soft tissue sarcoma.
    Andreou D; Werner M; Pink D; Traub F; Schuler MK; Gosheger G; Jobke B; Reichardt P; Tunn PU
    Int J Hyperthermia; 2016; 32(2):159-64. PubMed ID: 26670477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; van Geel AN; Eggermont AM
    Cancer; 2006 Jan; 106(1):156-62. PubMed ID: 16323177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperthermic isolated limb perfusion in locally advanced limb soft tissue sarcoma: A 24-year single-centre experience.
    Rastrelli M; Campana LG; Valpione S; Tropea S; Zanon A; Rossi CR
    Int J Hyperthermia; 2016; 32(2):165-72. PubMed ID: 26608883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma.
    Olieman AF; Pras E; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):807-14. PubMed ID: 9531364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
    Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
    Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy.
    Huis In 't Veld EA; Grünhagen DJ; Deroose JP; Nijsten TEC; Wouters MWJM; Verhoef C; van Houdt WJ; Hayes AJ
    Br J Cancer; 2018 Aug; 119(4):429-434. PubMed ID: 29961756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable sSewart-Treves lymphangiosarcoma.
    Lans TE; de Wilt JH; van Geel AN; Eggermont AM
    Ann Surg Oncol; 2002 Dec; 9(10):1004-9. PubMed ID: 12464594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
    Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
    Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
    Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.